Literature DB >> 19470741

Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients.

Bas Kreike1, Hans Halfwerk, Nicola Armstrong, Peter Bult, John A Foekens, Sanne C Veltkamp, Dimitry S A Nuyten, Harry Bartelink, Marc J van de Vijver.   

Abstract

PURPOSE: The majority of patients with early-stage breast cancer are treated with breast-conserving therapy (BCT). Several clinical risk factors are associated with local recurrence (LR) after BCT but are unable to explain all instances of LR after BCT. Here, gene expression microarrays are used to identify novel risk factors for LR after BCT. EXPERIMENTAL
DESIGN: Gene expression profiles of 56 primary invasive breast carcinomas from patients who developed a LR after BCT were compared with profiles of 109 tumors from patients who did not develop a LR after BCT. Both unsupervised and supervised methods of classification were used to separate patients into groups corresponding to disease outcome. In addition, for 15 patients, the gene expression profile in the recurrence was compared with that of the primary tumor.
RESULTS: The two main clusters found by hierarchical cluster analysis of all 165 primary invasive breast carcinomas revealed no association with LR. Predefined gene sets (molecular subtypes and "chromosomal instability" signature) are associated with LR (P = 0.0002 and 0.003, respectively). Significant analysis of microarrays revealed an association between LR and cell proliferation, not captured by histologic grading. Class prediction analysis constructed a gene classifier, which was successfully validated, cross-platform, on an independent data set of 161 patients (log-rank P = 0.041). In multivariate analysis, young age was the only independent predictor of LR.
CONCLUSIONS: We have constructed and cross-platform validated a gene expression profile predictive for LR after BCT, which is characterized by genes involved in cell proliferation but not a surrogate for high histologic grade.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19470741     DOI: 10.1158/1078-0432.CCR-08-2644

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Telomere length variation in normal epithelial cells adjacent to tumor: potential biomarker for breast cancer local recurrence.

Authors:  Xin Zhou; Alan K Meeker; Kepher H Makambi; Ourania Kosti; Bhaskar V S Kallakury; Mary K Sidawy; Christopher A Loffredo; Yun-Ling Zheng
Journal:  Carcinogenesis       Date:  2011-11-09       Impact factor: 4.944

2.  Integrating Radiosensitivity and Immune Gene Signatures for Predicting Benefit of Radiotherapy in Breast Cancer.

Authors:  Yi Cui; Bailiang Li; Erqi L Pollom; Kathleen C Horst; Ruijiang Li
Journal:  Clin Cancer Res       Date:  2018-06-19       Impact factor: 12.531

3.  Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study.

Authors:  Lawrence J Solin; Robert Gray; Lori J Goldstein; Abram Recht; Frederick L Baehner; Steven Shak; Sunil Badve; Edith A Perez; Lawrence N Shulman; Silvana Martino; Nancy E Davidson; George W Sledge; Joseph A Sparano
Journal:  Breast Cancer Res Treat       Date:  2012-05-01       Impact factor: 4.872

4.  The 21-gene recurrence score and locoregional recurrence in breast cancer patients.

Authors:  Naresh K Jegadeesh; Sunjin Kim; Roshan S Prabhu; Gabriela M Oprea; David S Yu; Karen G Godette; Amelia B Zelnak; Donna Mister; Jeffrey M Switchenko; Mylin A Torres
Journal:  Ann Surg Oncol       Date:  2014-12-04       Impact factor: 5.344

5.  Validation of a radiosensitivity molecular signature in breast cancer.

Authors:  Steven A Eschrich; William J Fulp; Yudi Pawitan; John A Foekens; Marcel Smid; John W M Martens; Michelle Echevarria; Vidya Kamath; Ji-Hyun Lee; Eleanor E Harris; Jonas Bergh; Javier F Torres-Roca
Journal:  Clin Cancer Res       Date:  2012-07-25       Impact factor: 12.531

6.  Risk stratification in ductal carcinoma in situ: the role of genomic testing.

Authors:  Gary M Freedman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

7.  Co-overexpression of GEP100 and AMAP1 proteins correlates with rapid local recurrence after breast conservative therapy.

Authors:  Rumiko Kinoshita; Jin-Min Nam; Yoichi M Ito; Kanako C Hatanaka; Ari Hashimoto; Haruka Handa; Yutaro Otsuka; Shigeru Hashimoto; Yasuhito Onodera; Mitsuchika Hosoda; Shunsuke Onodera; Shinichi Shimizu; Shinya Tanaka; Hiroki Shirato; Mishie Tanino; Hisataka Sabe
Journal:  PLoS One       Date:  2013-10-07       Impact factor: 3.240

8.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

Authors:  Alastair M Thompson; Lee B Jordan; Philip Quinlan; Elizabeth Anderson; Anthony Skene; John A Dewar; Colin A Purdie
Journal:  Breast Cancer Res       Date:  2010-11-08       Impact factor: 6.466

9.  Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment.

Authors:  Marc A Bollet; Alexia Savignoni; Leanne De Koning; Carine Tran-Perennou; Catherine Barbaroux; Armelle Degeorges; Brigitte Sigal-Zafrani; Geneviève Almouzni; Paul Cottu; Rémy Salmon; Nicolas Servant; Alain Fourquet; Patricia de Cremoux
Journal:  Breast Cancer Res       Date:  2009-07-28       Impact factor: 6.466

10.  Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.

Authors:  Fabien Reyal; David Hajage; Alexia Savignoni; Jean-Guillaume Feron; Marc Andrew Bollet; Youlia Kirova; Alain Fourquet; Jean-Yves Pierga; Paul Cottu; Veronique Dieras; Virginie Fourchotte; Fatima Laki; Severine Alran; Bernard Asselain; Anne Vincent-Salomon; Brigitte Sigal-Zafrani; Xavier Sastre-Garau
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.